Mangrove Partners

0

Mangrove Questions Asta FundingI Governance ($121M)

Purpose of Transaction. Item 4 of the Schedule 13D is hereby amended and supplemented by inserting the following text at the end thereof: As a result of the Issuer’s announcement of a “Dutch Auction” tender offer of shares of its own Common Stock and the Issuer’s unfair characterizations of our Offer we intend to seek representation…

0

Mangrove Goes Activist on RPX Corp ($578M)

Mangrove Partners disclosed ownership of 2,580,986 shares (5%) acquired at an average cost of $10.61 or 5% below current price of $11.20 per share. The Reporting Persons purchased the securities of the Issuer reported herein based on their belief that such securities are undervalued and represent an attractive investment opportunity. Depending upon overall market conditions,…

0

Asta Funding Wont Talk to Mangrove ($97M)

Mangrove Partners disclosed ownership of 2,102,427 shares (17.4%) acquired at an average cost of $8.31 per share or 3% above current price of $8.04. The Reporting Persons purchased the Shares based on the Reporting Persons’ belief that the Shares, when purchased, were undervalued and represented an attractive investment opportunity.  Depending upon overall market conditions, other investment…

Mangrove Demands HLSS Cut Ties with Ocwen

The Mangrove Partners Master Fund, Ltd., a significant shareholder of Home Loan Servicing Solutions, Ltd. (HLSS), today announced it has delivered a letter to the members of HLSS’s Board of Directors. The full text of the letter follows and has been posted to www.freeHLSS.com: The Board of Directors Home Loan Servicing Solutions, Ltd. c/o Intertrust…

Mangrove Sends Another Letter to CPEX Pharma

    (See earlier posts on CPEX dated 3/3/11, 2/28/11 and 1/31/11)    Nathaniel August    Mangrove Partners   10 East 53rd Street, 31st Floor New York, NY 10022 March 16, 2011 The Board of Directors CPEX Pharmaceuticals, Inc. 2 Holland Way Exeter, NH 03833    Dear Sirs: We are writing to inform the Board of Directors of CPEX…

CPEX Pharma Addresses Mangrove’s Allegations

(See earlier posts on CPEX dated 2/28/11 and 1/31/11) EXETER, N.H.–(BUSINESS WIRE)– CPEX Pharmaceuticals, Inc. (NASDAQ:CPEX – News) today issued a letter to its stockholders regarding its proposal to approve the merger agreement with FCB I Holdings Inc., under which CPEX stockholders will receive $27.25 per share in cash, and addressing misleading and inaccurate statements…

Mangrove Issues Press Release on CPEX Pharma

(See earlier post on CPEX dated 1/31/11) MANGROVE PARTNERS QUESTIONS THE PROPOSED SALE OF CPEX PHARMACEUTICALS AND INTENDS TO VOTE “NO” ON THE MERGER Special Meeting Scheduled to Take Place March 24, 2011 New York, New York – February 28, 2011 – Mangrove Partners, owners of 149,373 shares representing approximately 5.71% of the outstanding shares…

Mangrove Partners Opposes CPEX Deal

Nathaniel August Mangrove Partners 10 East 53rd Street, 31st Floor New York, NY 10022 January 28, 2011 The Board of Directors CPEX Pharmaceuticals, Inc. 2 Holland Way Exeter, NH 03833 Dear Sirs: I am writing you in our capacity as the investment manager for The Mangrove Partners Fund, L.P., owner of 139,017 shares of CPEX…

Get insights in your inbox with the Oozing Alpha monthly newsletter.
Join Now!
Newsletter